Fate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered … – StreetInsider.com
|
Fate Therapeutics (FATE) Reports Generation of CAR-targeted, TCR-null CD8aB + T Cells from Clonal Engineered …
StreetInsider.com Fate Therapeutics, Inc. (NASDAQ: FATE) announced today the generation of chimeric antigen receptor (CAR)-targeted CD8αβ+ T cells from a clonal engineered master pluripotent cell line (MPCL). The clonal engineered MPCL was created from an induced … |
